
5 Things to Know About 340B
As the date for the comment period on the proposed guidance by HHS on 340B drug pricing draws near, read about the program and its impact on healthcare overall.
The federal 340B Drug Pricing Program, initiated in 1992, requires pharmaceutical manufacturers participating in the Medicaid Drug Rebate Program to negotiate a drug pricing agreement with HHS—the manufacturer will provide specified discounts on “covered outpatient drugs” to government-supported facilities. The program enables covered entities to stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services. As the date for the comment period on the proposed guidance by HHS draws near (October 27, 2015), the following information will help provide a better flavor for the program and some of the controversies associated with it.
1. GAO Report Highlights Unlawful Spending By Hospitals Under 340B
A
2. Oncology Drugs Responsible for Much of the 340B Spending
A
3. 340B and Orphan Drugs
A judge recently
4. Impact of the Proposed Rule Changes to 340B
A new draft guidance by HHS and HRSA, released August 27, 2015, could significantly reduce savings and might involve more rigorous compliance oversight. While HRSA will be accepting comments on these proposed guidelines till October 27, 2015, there is no guarantee that the language of the guidance will be altered. Read an expert evaluation of the rules and their expected impact in
5. A Community Practice Oncologist Shares His Opinion on the 340B Program
Bruce J. Gould, MD, medical director of Northwest Georgia Oncology Centers in Marietta, GA, in an interview with
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.